Getting My ABBV-744 BRD4 inhibitor clinical efficacy in refractory cancers To Work
In Phase C, contributors will obtain ABBV-744 and oral navitoclax. In Phase D, participants will get ABBV-744 and ruxolitinib. Contributors will obtain treatment until eventually ailment progression or maybe the participants are not able to tolerate the study drugs.Attainable new ways with the prognosis and treatment of AML. (A) The identification